Investors bought shares of Allergan PLC (NYSE:AGN) on weakness during trading on Friday. $190.43 million flowed into the stock on the tick-up and $128.10 million flowed out of the stock on the tick-down, for a money net flow of $62.33 million into the stock. Of all companies tracked, Allergan PLC had the 24th highest net in-flow for the day. Allergan PLC traded down ($1.70) for the day and closed at $242.51

Several equities analysts recently weighed in on AGN shares. Cowen and Company reaffirmed a “buy” rating on shares of Allergan PLC in a research report on Tuesday, April 5th. Leerink Swann reaffirmed a “buy” rating and set a $340.00 price objective on shares of Allergan PLC in a research report on Tuesday, April 5th. Nomura Holdings Inc. reaffirmed a “buy” rating and set a $330.00 price objective (down previously from $350.00) on shares of Allergan PLC in a research report on Tuesday, April 5th. Canaccord Genuity reaffirmed a “buy” rating and set a $320.00 price objective (down previously from $340.00) on shares of Allergan PLC in a research report on Thursday, March 31st. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $335.00 price objective on shares of Allergan PLC in a research report on Thursday, June 9th. Six equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $306.06.

The stock has a market cap of $95.93 billion and a P/E ratio of 21.70. The company’s 50 day moving average is $238.09 and its 200 day moving average is $257.62.

Allergan PLC (NYSE:AGN) last released its quarterly earnings data on Tuesday, May 10th. The company reported $3.04 EPS for the quarter, beating the consensus estimate of $3.03 by $0.01. The company earned $3.80 billion during the quarter, compared to analyst estimates of $3.97 billion. Allergan PLC’s revenue was up 48.1% on a year-over-year basis. Analysts expect that Allergan PLC will post $14.20 earnings per share for the current fiscal year.

In related news, Director Nesli Basgoz sold 459 shares of the stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $225.10, for a total value of $103,320.90. Following the sale, the director now owns 5,242 shares in the company, valued at approximately $1,179,974.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Maria Teresa Hilado purchased 661 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The stock was acquired at an average price of $241.57 per share, for a total transaction of $159,677.77. Following the purchase, the chief financial officer now owns 11,957 shares in the company, valued at approximately $2,888,452.49. The disclosure for this purchase can be found here.

A number of large investors have bought and sold shares of the stock. State of Tennessee Treasury Department boosted its stake in Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock worth $145,669,000 after buying an additional 268,357 shares during the period. Employees Retirement System of Texas boosted its stake in Allergan PLC by 265.5% in the fourth quarter. Employees Retirement System of Texas now owns 148,258 shares of the company’s stock worth $46,331,000 after buying an additional 107,700 shares during the period. Affinity Investment Advisors LLC boosted its stake in Allergan PLC by 0.5% in the fourth quarter. Affinity Investment Advisors LLC now owns 64,560 shares of the company’s stock worth $20,175,000 after buying an additional 299 shares during the period. Edgewood Management LLC boosted its stake in Allergan PLC by 10.9% in the fourth quarter. Edgewood Management LLC now owns 1,459,579 shares of the company’s stock worth $456,118,000 after buying an additional 143,657 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Allergan PLC by 6.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,596,389 shares of the company’s stock worth $498,895,000 after buying an additional 103,314 shares during the period.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.